Ellevest Inc’s Ligand Pharmaceuticals LGND Stock Holding History

Ellevest Inc’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-8	Closed	-$588	–	1053
2023 Q1	$588	Buy	+8	New	+$569	﹤0.01%	1659

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Ellevest Inc's LGND Position: Q2 2023 in Review

Ellevest Inc sold out of Ligand Pharmaceuticals (LGND) in Q2 2023, closing a stake of 8 shares — an estimated $588 sold.

Ellevest Inc first reported a position in LGND in Q1 2023 and held it in 1 quarter. The position peaked at $588 in Q1 2023. 204 funds tracked by Wall St. Rank hold LGND as of Q2 2023.

Ellevest Inc reported no remaining Ligand Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Ellevest Inc sold 8 Ligand Pharmaceuticals shares in Q2 2023, an estimated $588.
Ellevest Inc first reported a position in Ligand Pharmaceuticals in Q1 2023 and held it in 1 quarter.
Ellevest Inc's Ligand Pharmaceuticals position peaked at $588 in Q1 2023.
204 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2023.

Based on Ellevest Inc's 13F filing for Q2 2023, filed 9 Aug 2023.